ライフサイエンスコーパス: sensory neuropathy

1 disabling neuropathic pain disorder due to a sensory neuropathy.

2 from physiological and structural indices of sensory neuropathy.

3 levant therapeutic target for HIV-associated sensory neuropathy.

4 increased insulin sensitivity, and previous sensory neuropathy.

5 ompounds that may prevent development of the sensory neuropathy.

6 d were fatigue, constipation, and peripheral sensory neuropathy.

7 ediabetic and develop insulin resistance and sensory neuropathy.

8 nausea or vomiting, headache, and transient sensory neuropathy.

9 ot genotype-specific in hereditary motor and sensory neuropathy.

10 Tooth disease, a severe hereditary motor and sensory neuropathy.

11 prague-Dawley rat strain with an early onset sensory neuropathy.

12 thy with associated radiculopathy and distal sensory neuropathy.

13 nic hyperglycemia results in a predominantly sensory neuropathy.

14 is, manifested clinically as a predominantly sensory neuropathy.

15 or days of therapy and a chronic, cumulative sensory neuropathy.

16 icantly mitigating oxaliplatin-induced acute sensory neuropathy.

17 y contribute to the pathogenesis of diabetic sensory neuropathy.

18 Total dose is limited by development of a sensory neuropathy.

19 s potentially efficacious for human diabetic sensory neuropathy.

20 g cells may contribute to the HIV-associated sensory neuropathy.

21 ratory chain and function and resulting in a sensory neuropathy.

22 the invariant presence of a prominent axonal sensory neuropathy.

23 in prediabetic mice while protecting against sensory neuropathy.

24 hereditary spastic paraplegia and hereditary sensory neuropathy.

25 th a dominantly inherited late-onset painful sensory neuropathy.

26 ), which has been associated with hereditary sensory neuropathy.

27 Eleven patients developed grade 3 sensory neuropathy.

28 ebrile seizures and recently (5) small fibre sensory neuropathy.

29 (CMT1C) is a dominantly inherited motor and sensory neuropathy.

30 of cisplatin chemotherapy causes substantial sensory neuropathy.

31 a musculorum (dt) mice results in hereditary sensory neuropathy.

32 trategy for attenuating cisplatin-associated sensory neuropathy.

33 te the importance of this model for study of sensory neuropathy.

34 e may be the initiating event in HIV-induced sensory neuropathy.

35 uninfected patients or HIV patients without sensory neuropathy.

36 ative sensory testing were consistent with a sensory neuropathy.

37 unrelated patients with hereditary motor and sensory neuropathy.

38 nt with a severe, early-onset proprioceptive sensory neuropathy.

39 intact animals, was absent after large-fiber sensory neuropathy.

40 nced grade 2, and none experienced grade 3/4 sensory neuropathy.

41 linated, but not myelinated nerve fibres, in sensory neuropathies.

42 le of disrupted ErbB signaling in peripheral sensory neuropathies.

43 fore an excellent model for human hereditary sensory neuropathies.

44 e beneficial in the treatment of large-fiber sensory neuropathies.

45 lications for pain sensitivity in peripheral sensory neuropathies.

46 es and in 1 patient because of a generalized sensory neuropathy; 1 patient refused to continue taking

47 vomiting (13%), nausea (11%), and peripheral sensory neuropathy (11%) in arm A, and diarrhea (33%), f

48 included grade 4 neutropenia (24%), grade 3 sensory neuropathy (11%), and grade 4 febrile neutropeni

49 21%), thrombocytopenia (14%), and peripheral sensory neuropathy (12%).

50 treatment-related events included peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgi

51 Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and ne

52 %), as well as a higher rate of grade 2 to 4 sensory neuropathy (26% vs. 18%); however, they had a lo

53 patients), rash (5 patients), and peripheral sensory neuropathy (3 patients).

54 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients).

55 /vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%).

56 bocytopenia, 2% and 15%; anemia, 5% and 11%; sensory neuropathy, 3% and 0.8%; fatigue, 5% and 12%; pe

57 v 25.8%), febrile neutropenia (4.1% v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or

58 y common groups such as hereditary motor and sensory neuropathy (40/100,000) and mitochondrial disord

59 usion-related reaction (45%), and peripheral sensory neuropathy (44%).

60 nd pyrexia (52% each), nausea and peripheral sensory neuropathy (48% each), and dyspnea (40%) were th

61 ia (2.7% v 3.6%), fatigue (7.9% v 3.4%), and sensory neuropathy (5.5% v 0%).

62 Common treatment-related toxicities included sensory neuropathy (53%), fatigue (50%), and neutropenia

63 ogic and hematologic, including grade 1 to 2 sensory neuropathy (55%), grade 3 to 4 neutropenia (35%)

64 es with HSAN I, 60 individuals with sporadic sensory neuropathy, 6 HSAN II families, 20 Charcot-Marie

65 The most common AEs were peripheral sensory neuropathy (78%), fatigue (44%), and nausea (44%

66 Most common toxicities included sensory neuropathy (80%) and fatigue (64%), with only 27

67 ild to moderate, the most common being acute sensory neuropathy (85%).

68 he brentuximab vedotin group were peripheral sensory neuropathy (94 [56%] of 167 patients vs 25 [16%]

69 sly uncharacterized complex axonal motor and sensory neuropathy accompanied by severe nonprogressive

70 equired that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminolo

71 found between groups; only grade 2 or higher sensory neuropathy adverse events persisted at 24 months

72 Sensory neuropathy (all grade 1-3) was recorded in 17 (9

73 ing, and potential therapeutic treatment, of sensory neuropathies and a number of neurological diseas

74 n and most frequent of a group of congenital sensory neuropathies and is characterized by widespread

75 he field of axonal CMT and have relevance to sensory neuropathies and motor neuron disorders.

76 nful neuropathy and 28 without pain, 26 with sensory neuropathy and 24 with sensory and motor neuropa

77 Mutated CCT4/5 subunits cause sensory neuropathy and CCT5 expression is decreased in A

78 A triad of hearing loss, sensory neuropathy and cognitive decline remains as the

79 of three patients experienced a DLT (grade 3 sensory neuropathy and febrile neutropenia).

80 xanes; such a neuropathy usually presents as sensory neuropathy and is more common with paclitaxel th

81 Sensory neuropathy and neutropenia were more common with

82 Sensory neuropathy and neutropenia were significantly mo

83 eutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0

84 y adult-onset retinitis pigmentosa, anosmia, sensory neuropathy and phytanic acidaemia.

85 (-/-) mice as an animal model of small fiber sensory neuropathy and provide new insight regarding the

86 ation of results from STZ models of diabetic sensory neuropathy and strongly argues that more refined

87 n important pathogenetic role in nociceptive sensory neuropathy and that C-peptide replacement may be

88 T was grade 3 pharyngolaryngeal dysesthesia, sensory neuropathy, and ataxia at 160 mg/m2.

89 de 3 events of neutropenia (14%), peripheral sensory neuropathy, and hyperkalemia (9% each).

90 n adverse events were fatigue, constipation, sensory neuropathy, and infection; there was no treatmen

91 ade 3 hypothyroidism, and grade 3 peripheral sensory neuropathy, and one case of grade 4 pneumonitis.

92 icities included myelosuppression, vomiting, sensory neuropathy, and ototoxicity and were worse with

93 l mechanism for dideoxynucleoside-associated sensory neuropathy, and questions arise about enhanced r

94 s and were characterized by cough, asthenia, sensory neuropathy, anorexia, serum sickness, and hypert

95 Hereditary sensory neuropathies are a class of disorders marked by

96 Late-onset painful sensory neuropathies are usually acquired conditions ass

97 as diabetic and human immunodeficiency virus sensory neuropathies) are characterized by distal axonal

98 ognitive disorders, vacuolar myelopathy, and sensory neuropathies associated with HIV are the most co

99 The sensory neuropathies associated with HIV infection are a

100 he SLC12A6 gene, causes hereditary motor and sensory neuropathy associated with agenesis of the corpu

101 ogical disease (brainstem encephalopathy and sensory neuropathy being common extracerebellar manifest

102 1 (GDAP1) cause severe peripheral motor and sensory neuropathies called Charcot-Marie-Tooth disease.

103 Chronic sensory neuropathy can be dose limiting and may have det

104 is an uncommon form of hereditary motor and sensory neuropathy caused by mutations in the P(0) myeli

105 T4B) is a demyelinating hereditary motor and sensory neuropathy characterized by abnormal folding of

106 athogenic mutations for hereditary motor and sensory neuropathy, distal hereditary motor neuropathy,

107 nosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic

108 autosomal-dominant disorder that leads to a sensory neuropathy due to mutations in the serine palmit

109 ients), hypokalaemia (six [33%]), peripheral sensory neuropathy (five [28%]), diarrhoea (five [28%]),

110 of 45), anaemia (five [11%]), and peripheral sensory neuropathy (four [9%]).

111 atients experienced more frequent and severe sensory neuropathy (grade 1 to 4; 8% v 30%).

112 fect large nerve fibers; painful small fiber sensory neuropathy has not previously been described in

113 HIV-associated sensory neuropathy (HIV-SN) is currently the most common

114 uman immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) is difficult but needed for

115 uman immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) is the most common neurologi

116 t in human immunodeficiency virus-associated sensory neuropathy (HIV-SN), damaged mtDNA accumulates i

117 me 17p11.2 duplication (hereditary motor and sensory neuropathy-HMSN Ia).

118 The autosomal dominant peripheral sensory neuropathy HSAN1 results from mutations in the L

119 sities in 35 patients confirmed pretreatment sensory neuropathy in 20% and new or worsening neuropath

120 (day 21), consistent with the development of sensory neuropathy in SIV-infected macaques.

121 cy of neurotrophic or regenerative drugs for sensory neuropathies including those caused by HIV, diab

122 compasses axonal and demyelinating motor and sensory neuropathies, including four young patients pres

123 Small fiber sensory neuropathy is a common disorder in which progres

124 IGNIFICANCE STATEMENT Painful HIV-associated sensory neuropathy is a neurological complication of HIV

125 We hypothesized that diabetic sensory neuropathy is associated with activation of apop

126 The painful sensory neuropathy is associated with the use of dideoxy

127 any time, but early in the IBD course, pure sensory neuropathy is more common.

128 jority of patients, the cause of small fiber sensory neuropathy is unknown, and treatment options are

129 they ensheath cause the hereditary motor and sensory neuropathies known as Charcot-Marie-Tooth (CMT)

130 febrile neutropenia (9%, 3%, 3%; P < .001), sensory neuropathy (< 1%, 7%, 6%; P < .001), and diarrhe

131 nduced by streptozotocin (STZ) resulted in a sensory neuropathy manifest by a decrease in the foot se

132 tment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and di

133 e patient in the 1.5 mg/m2 group had grade 3 sensory neuropathy; no grade 3 sensory neuropathy was se

134 Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4

135 Grade 3 sensory neuropathy occurred in 14% of patients, and 22.7

136 lecular genetics of the hereditary motor and sensory neuropathies of autosomal dominant and X-linked

137 The concept of a severe motor-sensory neuropathy of acute onset caused by an immune at

138 hy some individuals develop an acute painful sensory neuropathy on sustained cold exposure is not yet

139 ed to those of type III hereditary motor and sensory neuropathy or Dejerine-Sottas disease.

140 toplasmic dynein can either result in a pure sensory neuropathy or in a sensory neuropathy with motor

141 HIV-associated sensory neuropathy remains the most common neurological

142 Our study indicates a prominent sensory neuropathy resulting from periaxin gene mutation

143 lkan Gypsies and termed hereditary motor and sensory neuropathy-Russe (HMSN-R).

144 e for the important complication of diabetic sensory neuropathy, since hyperglycemia for longer than

145 uman immunodeficiency virus (HIV)-associated sensory neuropathy (SN) is the most common neurological

146 Sensory neuropathy symptoms were more prominent than wer

147 spectively examined the relationship between sensory neuropathy symptoms, falls, and fall-related inj

148 Of the sensory neuropathy symptoms, numbness and tingling were

149 ng side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime.

150 type, SIMPLE develop a late-onset motor and sensory neuropathy that recapitulates key clinical featu

151 fatigue, depressed consciousness, dizziness, sensory neuropathy, tremor, constipation, dyspnea, hypox

152 Hereditary sensory neuropathy type 1 (HSN1) is a dominantly inherit

153 Hereditary sensory neuropathy type 1 (HSN1, MIM 162400) genetically

154 Hereditary sensory neuropathy type 1 is an autosomal-dominant disor

155 ng hereditary spastic paraplegia, hereditary sensory neuropathy type 1, and non-5q spinal muscular at

156 mapped to this region, including hereditary sensory neuropathy type 1, self-healing squamous epithel

157 tly inactivate SPT similar to the hereditary sensory neuropathy type 1-like mutations in Lcb1p.

158 at encodes for SPT subunits cause hereditary sensory neuropathy type 1.

159 palmitoyltransferase (SPT), cause hereditary sensory neuropathy type I .

160 esidues that are mutated to cause hereditary sensory neuropathy type I reside in a highly conserved r

161 lar atrophy (SPSMA) and hereditary motor and sensory neuropathy type IIC (HMSN IIC, also known as HMS

162 for which is duplicated in hereditary motor sensory neuropathy type la, can also induce EAN.

163 has been designated as hereditary motor and sensory neuropathy type VI (HMSN VI).

164 The severity of the resultant sensory neuropathy was compared with behavioral, physiol

165 r in both arms, as was grade 3 rash, whereas sensory neuropathy was higher in the concurrent arm (15%

166 Sensory neuropathy was mild with grade 3 neurotoxicity r

167 Grade 3 sensory neuropathy was more common in the ABI-007 arm th

168 Grade 2 or 3 sensory neuropathy was present in 10 patients (53%) over

169 p had grade 3 sensory neuropathy; no grade 3 sensory neuropathy was seen in the 1.3 mg/m2 group.

170 Sensory neuropathy was seen more commonly than motor axo

171 Minimal hematologic toxicity and no grade 3 sensory neuropathy were noted.

172 nausea, fatigue, arthralgias, and peripheral sensory neuropathy, were mild to moderate and matched th

173 In 4 infants with a new lethal autonomic sensory neuropathy with clinical features similar to fam

174 result in a pure sensory neuropathy or in a sensory neuropathy with motor neuron involvement.

175 awling (Swl) mutation display an early-onset sensory neuropathy with muscle spindle deficiency.

176 tive diseases including hereditary motor and sensory neuropathy with proximal dominant involvement (H

177 We produced a dose-dependent large-fiber sensory neuropathy, without detrimental effects on gener